Skip to main content
. Author manuscript; available in PMC: 2022 Jan 11.
Published in final edited form as: J Allergy Clin Immunol. 2021 May 24;149(1):410–421.e7. doi: 10.1016/j.jaci.2021.04.036

FIG 2.

FIG 2.

Kaplan-Meier survival curves depicting OS and GFFS by underlying diagnosis (A), donor type (smallest subgroup of mismatched unrelated donor and cord excluded, n = 5) (B), conditioning intensity (smallest subgroup of nonmyeloablative/immunosuppression only conditioning excluded, n = 1) (C), or serotherapy choice (of note, follow up is shorter for smaller subgroups of horse antithymocyte globulin [ATG] and intermediate timing alemtuzumab) (D). NS, Not significant.